Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

caracemide

An agent derived from acetohydroxamic acid with potential antineoplastic activity. Caracemide inhibits ribonuclease reductase, resulting in decreased DNA synthesis and tumor growth; it also inhibits acetylcholinesterase. In vivo, caracemide contributes to the formation of the neurotoxin methyl isocyanate; this effect, along with the agent's acetylcholinesterase activity, may be responsible for the severe central nervous system toxicity observed in clinical trials.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Chemical structure:	acetamide, N-[(methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]-(9CI) N-acetyl-N-(methylcarbamoyloxy)-N'-methylurea
IND number:	22624
NSC code:	253272

caracemide

Search NCI's Drug Dictionary